STAT3 and acquired polycythemia vera: The FDA has approved ruxolitinib (RUX), a Janus kinase (JAK)/STAT-3 inhibitor, for the treatment of primary myelofibrosis, polycythemia vera [14], and vitiligo [15], providing clinical validation of its effectiveness in inhibiting STAT-3.